Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 9/2021

Open Access 01-09-2021 | Original Article – Cancer Research

Why so few Nobel Prizes for cancer researchers? An analysis of Nobel Prize nominations for German physicians with a focus on Ernst von Leyden and Karl Heinrich Bauer

Authors: Nils Hansson, Giacomo Padrini, Friedrich H. Moll, Thorsten Halling, Carsten Timmermann

Published in: Journal of Cancer Research and Clinical Oncology | Issue 9/2021

Login to get access

Abstract

Purpose

To date, 11 scientists have received the Nobel Prize for discoveries directly related to cancer research. This article provides an overview of cancer researchers nominated for the Nobel Prize from 1901 to 1960 with a focus on Ernst von Leyden (1832–1910), the founder of this journal, and Karl Heinrich Bauer (1890–1978).

Methods

We collected nominations and evaluations in the archive of the Nobel committee of physiology or medicine in Sweden to identify research trends and to analyse oncology in a Nobel Prize context.

Results

We found a total of 54 nominations citing work on cancer as motivation for 11 candidates based in Germany from 1901 to 1953. In the 1930s, the US became the leading nation of cancer research in a Nobel context with nominees like Harvey Cushing (1869–1939) and George N. Papanicolaou (1883–1962).

Discussion

The will of Alfred Nobel stipulates that Nobel laureates should have “conferred the greatest benefit to mankind”. Why were then so few cancer researchers recognized with the Nobel medal from 1901 to 1960? Our analysis of the Nobel dossiers points at multiple reasons: (1) Many of the proposed cancer researchers were surgeons, and surgery has a weak track record in a Nobel context; (2) several scholars were put forward for clinical work and not for basic research (historically, the Nobel committee has favoured basic researchers); (3) the scientists were usually not nominated for a single discovery, but rather for a wide range of different achievements.
Literature
go back to reference Atzl I, Helms R (2012) Die Gründung des Comités für Krebssammelforschung im Jahr 1900. In: Die Geschichte der Deutschen Krebsgesellschaft. Deutsche Krebsgesellschaft, München Atzl I, Helms R (2012) Die Gründung des Comités für Krebssammelforschung im Jahr 1900. In: Die Geschichte der Deutschen Krebsgesellschaft. Deutsche Krebsgesellschaft, München
go back to reference Bartholomew JR (2002) Katsusaburo Yamagiwa’s Nobel candidacy: physiology or medicine in the 1920s. In: Crawford E (ed) Historical Studies in the Nobel Archives. The Prize in Science and Medicine. Universal Academy Press, pp 107–131 Bartholomew JR (2002) Katsusaburo Yamagiwa’s Nobel candidacy: physiology or medicine in the 1920s. In: Crawford E (ed) Historical Studies in the Nobel Archives. The Prize in Science and Medicine. Universal Academy Press, pp 107–131
go back to reference Bauer KH (1926) Rassenhygiene. Ihre biologischen Grundlagen. Quelle & Meyer, Leipzig Bauer KH (1926) Rassenhygiene. Ihre biologischen Grundlagen. Quelle & Meyer, Leipzig
go back to reference Bauer KH (1928) Mutationstheorie der Geschwulstentstehung. Übergang von Körperzellen in Geschwulstzellen durch Gen-Änderung. Julius Springer, Berlin Bauer KH (1928) Mutationstheorie der Geschwulstentstehung. Übergang von Körperzellen in Geschwulstzellen durch Gen-Änderung. Julius Springer, Berlin
go back to reference Bauer KH (1943) Die Mutationstheorie der Krebsentstehung im Lichte ihrer chemischen und physikalischen Beweismittel. Münchn Med Wschr 90:681–682 Bauer KH (1943) Die Mutationstheorie der Krebsentstehung im Lichte ihrer chemischen und physikalischen Beweismittel. Münchn Med Wschr 90:681–682
go back to reference Bauer KH (1949a) Zur Chemotherapie des Krebses mit mutativen Stoffen, insbesondere über mutative Syncarcinocolyse. Klin Wschr 27:159–163CrossRef Bauer KH (1949a) Zur Chemotherapie des Krebses mit mutativen Stoffen, insbesondere über mutative Syncarcinocolyse. Klin Wschr 27:159–163CrossRef
go back to reference Bauer KH (1949b) Das Krebsproblem: Einführung in die allgemeine Geschwulstlehre. Springer, BerlinCrossRef Bauer KH (1949b) Das Krebsproblem: Einführung in die allgemeine Geschwulstlehre. Springer, BerlinCrossRef
go back to reference Björk R (2001) Inside the Nobel Committee on Medicine. Prize Competition Procedures 1901–1950 and the Fate of Carl Neuberg. Minerva 39:393–408CrossRef Björk R (2001) Inside the Nobel Committee on Medicine. Prize Competition Procedures 1901–1950 and the Fate of Carl Neuberg. Minerva 39:393–408CrossRef
go back to reference Fangerau H (2010) Spinning the scientific web: Jacques Loeb (1859–1924) und sein Programm einer internationalen biomedizinischen Grundlagenforschung. Akademie-Verlag, BerlinCrossRef Fangerau H (2010) Spinning the scientific web: Jacques Loeb (1859–1924) und sein Programm einer internationalen biomedizinischen Grundlagenforschung. Akademie-Verlag, BerlinCrossRef
go back to reference Hansson N (2015) Karl Sudhoff und der Nobelpreis. Medizinhist J 50:393–400PubMed Hansson N (2015) Karl Sudhoff und der Nobelpreis. Medizinhist J 50:393–400PubMed
go back to reference Hansson N, Tuffs A (2016) Nominee and nominator, but never Nobel Laureate: Vincenz Czerny and the Nobel Prize. Langenbecks Arch Surg 401(8):1093–1096CrossRef Hansson N, Tuffs A (2016) Nominee and nominator, but never Nobel Laureate: Vincenz Czerny and the Nobel Prize. Langenbecks Arch Surg 401(8):1093–1096CrossRef
go back to reference Hansson N, Moll F, Schultheiss D, Krischel M (2016) Remembering Charles B. Huggins’ Nobel Prize for Hormonal Treatment of Prostatic Cancer at its 50th Anniversary. Eur Urol 69(6):971–972CrossRef Hansson N, Moll F, Schultheiss D, Krischel M (2016) Remembering Charles B. Huggins’ Nobel Prize for Hormonal Treatment of Prostatic Cancer at its 50th Anniversary. Eur Urol 69(6):971–972CrossRef
go back to reference Hansson N, Halling T, Moll F, Fangerau H (2017) Berühmte Gynäkologen: Deutsche Nobelpreiskandidaten in der Gynäkologie 1901–1920. Geburtshilfe Frauenheilkd 77(3):247–250 Hansson N, Halling T, Moll F, Fangerau H (2017) Berühmte Gynäkologen: Deutsche Nobelpreiskandidaten in der Gynäkologie 1901–1920. Geburtshilfe Frauenheilkd 77(3):247–250
go back to reference Hansson N, Jones DS, Schlich T (2019) Defining ‘cutting-edge’ Excellence: Awarding Nobel Prizes (or Not) to Surgeons. In: Hansson N, Halling T, Fangerau H (eds) Attributing Excellence in Medicine: The History of the Nobel Prize. Brill, pp 122–139 Hansson N, Jones DS, Schlich T (2019) Defining ‘cutting-edge’ Excellence: Awarding Nobel Prizes (or Not) to Surgeons. In: Hansson N, Halling T, Fangerau H (eds) Attributing Excellence in Medicine: The History of the Nobel Prize. Brill, pp 122–139
go back to reference Henschen F (1957) Min långa väg till Salamanca: en läkares liv. Bonniers, Stockholm Henschen F (1957) Min långa väg till Salamanca: en läkares liv. Bonniers, Stockholm
go back to reference Höffken K (2004) One hundred years of cancer research. J Cancer Res Clin Oncol 130:57–58CrossRef Höffken K (2004) One hundred years of cancer research. J Cancer Res Clin Oncol 130:57–58CrossRef
go back to reference Hüntelmann C (2018) Paul Ehrlich und der Nobelpreis. Die Konstruktion Wissenschaftlicher Exzellenz. Ber Wiss 41:47–72 Hüntelmann C (2018) Paul Ehrlich und der Nobelpreis. Die Konstruktion Wissenschaftlicher Exzellenz. Ber Wiss 41:47–72
go back to reference Kantha SS (2020) Cancer research recognized (and ignored) by the Nobel prizes. Indian J Cancer 57:376–377CrossRef Kantha SS (2020) Cancer research recognized (and ignored) by the Nobel prizes. Indian J Cancer 57:376–377CrossRef
go back to reference Kohl T (2016) Ernst von Leyden und die Institutionalisierung der Krebsforschung zwischen 1896 und 1911. NTM 24:39–60CrossRef Kohl T (2016) Ernst von Leyden und die Institutionalisierung der Krebsforschung zwischen 1896 und 1911. NTM 24:39–60CrossRef
go back to reference Leyden E (1863) Die graue Degeneration der hinteren Rückenmarksstränge, Berlin Leyden E (1863) Die graue Degeneration der hinteren Rückenmarksstränge, Berlin
go back to reference Lindner F (1991) In Memoriam Karl Heinrich Bauer Feier aus Anlaß des 100. Geburtstages 26. September 1990. Springer, Berlin Lindner F (1991) In Memoriam Karl Heinrich Bauer Feier aus Anlaß des 100. Geburtstages 26. September 1990. Springer, Berlin
go back to reference Löwy I, Gaudillière J-P (1998) Disciplining cancer: mice and the practice of genetic purity. In: Jean-Paul G, Ilana L (eds) The invisible industrialist: manufactures and the production of scientific knowledge. MacMillan, Basingstoke, pp 209–249CrossRef Löwy I, Gaudillière J-P (1998) Disciplining cancer: mice and the practice of genetic purity. In: Jean-Paul G, Ilana L (eds) The invisible industrialist: manufactures and the production of scientific knowledge. MacMillan, Basingstoke, pp 209–249CrossRef
go back to reference Rosenberg A (1912) Gedächtnisrede. Berliner Klin Wschr 49:237–239 Rosenberg A (1912) Gedächtnisrede. Berliner Klin Wschr 49:237–239
go back to reference Stolt CM, Klein G, Jansson AT (2013) An analysis of a wrong Nobel Prize—Johannes Fibiger, 1926: a study in Nobel archives. Emerg Infect Dis 19:660–663CrossRef Stolt CM, Klein G, Jansson AT (2013) An analysis of a wrong Nobel Prize—Johannes Fibiger, 1926: a study in Nobel archives. Emerg Infect Dis 19:660–663CrossRef
go back to reference Strong LC (1976) A Baconian in cancer research: autobiographical essay. Can Res 36:3545–3553 Strong LC (1976) A Baconian in cancer research: autobiographical essay. Can Res 36:3545–3553
go back to reference Timmermann C (2001) Constitutional medicine, neoromanticism, and the politics of antimechanism in interwar Germany. Bull Hist Med 75:717–739CrossRef Timmermann C (2001) Constitutional medicine, neoromanticism, and the politics of antimechanism in interwar Germany. Bull Hist Med 75:717–739CrossRef
go back to reference Timmermann C (2019) Moonshots at cancer: the Roche story. Editiones Roche, Basel Timmermann C (2019) Moonshots at cancer: the Roche story. Editiones Roche, Basel
go back to reference von Hecker E (1971) Karl Heinrich Bauer Zum 80. Geburtstag. In: Schipperges H (ed) Heidelberger Jahrbücher. Springer, Berlin/Heidelberg von Hecker E (1971) Karl Heinrich Bauer Zum 80. Geburtstag. In: Schipperges H (ed) Heidelberger Jahrbücher. Springer, Berlin/Heidelberg
go back to reference Voswinckel P (2014) Erinnerungsort Krebsbaracke. Klarstellungen um das erste interdisziplinäre Krebsforschungsinstitut in Deutschland (Berlin, Charité). DGHO Berlin Voswinckel P (2014) Erinnerungsort Krebsbaracke. Klarstellungen um das erste interdisziplinäre Krebsforschungsinstitut in Deutschland (Berlin, Charité). DGHO Berlin
go back to reference Voswinckel P (2019) Verwässerung und Verleugnung einer Gründungsgeschichte der Onkologie. Ernst von Leyden, Deutsche Gesellschaft für Hämatologie und Onkologie, Berlin Voswinckel P (2019) Verwässerung und Verleugnung einer Gründungsgeschichte der Onkologie. Ernst von Leyden, Deutsche Gesellschaft für Hämatologie und Onkologie, Berlin
go back to reference Wagner G, Mauerberger A (1989) Krebsforschung in Deutschland: Vorgeschichte und Geschichte des Deutschen Krebsforschungszentrums. Springer, BerlinCrossRef Wagner G, Mauerberger A (1989) Krebsforschung in Deutschland: Vorgeschichte und Geschichte des Deutschen Krebsforschungszentrums. Springer, BerlinCrossRef
Metadata
Title
Why so few Nobel Prizes for cancer researchers? An analysis of Nobel Prize nominations for German physicians with a focus on Ernst von Leyden and Karl Heinrich Bauer
Authors
Nils Hansson
Giacomo Padrini
Friedrich H. Moll
Thorsten Halling
Carsten Timmermann
Publication date
01-09-2021
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 9/2021
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-021-03671-x

Other articles of this Issue 9/2021

Journal of Cancer Research and Clinical Oncology 9/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine